技术评估：CC49人源化放射免疫缀合物，美国国立癌症研究所
Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute.
作者信息
Sheikh Nadeem
机构信息
Washington National Primate Research Center, Department of Pharmaceutics, University of Washington, 3000 Western Avenue, Seattle, WA 98121, USA.
出版信息
Curr Opin Mol Ther. 2003 Aug;5(4):428-32.
PMID:14513687
Abstract
The National Cancer Institute and the University of Alabama are developing radiolabeled humanized versions of the anticarcinoma monoclonal antibody CC49 devoid of the CH2 domain (designated HuCC49 delta CH2). The antibody is currently undergoing phase I trials for the potential treatment of various tumors.
摘要
美国国立癌症研究所和阿拉巴马大学正在研发去除CH2结构域的放射性标记人源化抗癌单克隆抗体CC49（命名为HuCC49 delta CH2）。该抗体目前正在进行I期试验，用于多种肿瘤的潜在治疗。
Zotero 插件